menu
    • menu
    [{"orgOrder":0,"company":"Minaris","sponsor":"MaxiVAX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"MVX-ONCO-2","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Minaris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Minaris \/ MaxiVAX","highestDevelopmentStatusID":"8","companyTruncated":"Minaris \/ MaxiVAX"},{"orgOrder":0,"company":"Minaris","sponsor":"Mendus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"DCP-001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Minaris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Minaris \/ Minaris","highestDevelopmentStatusID":"8","companyTruncated":"Minaris \/ Minaris"},{"orgOrder":0,"company":"Minaris","sponsor":"LIfT Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Neutrophil Progenitor-based Leukocyte Infusion Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Minaris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Minaris \/ Minaris","highestDevelopmentStatusID":"4","companyTruncated":"Minaris \/ Minaris"}]

    Find Clinical Drug Pipeline Developments & Deals by Minaris

    Menu

    Minaris

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Minaris

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Minaris

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neutrophil Progenitor-based Leukocyte Infusion Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : LIfT Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            LIfT BioSciences and Minaris Regenerative Medicine Enter into a Manufacturing Partnership

                            Details : The partnership is for the development and manufacturing of N-LIfT, LIfT’s first-in-class neutrophil progenitor based Leukocyte Infusion Therapy for the treatment of various cancer indications, including Pancreatic Cancer, Lung Cancer and other solid t...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 16, 2023

                            Lead Product(s) : Neutrophil Progenitor-based Leukocyte Infusion Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : LIfT Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Minaris

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Minaris

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DCP-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Mendus

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Mendus AB: Mendus Secures Manufacturing Partner For Establishing Potential Pivotal Trial-stage And Commercial ...

                            Details : DCP-001 is currently being evaluated in the ADVANCE II Phase 2 clinical trial to prevent cases of tumor recurrence in Acute Myeloid Leukemia (AML) and in the ALISON Phase 1 clinical trial in ovarian cancer.

                            Brand Name : DCP-001

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 17, 2022

                            Lead Product(s) : DCP-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Mendus

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Minaris

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Minaris

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MVX-ONCO-2

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : MaxiVAX

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing Partnership for MVX-ONCO-2 Cancer Immunot...

                            Details : Minaris will be responsible for the GMP manufacturing, freezing and shipping of the MVX-ONCO-2 capsules, which will be delivered to clinical sites. The autologous patients’ tumor cells will be processed at the clinical sites.

                            Brand Name : MVX-ONCO-2

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 22, 2021

                            Lead Product(s) : MVX-ONCO-2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : MaxiVAX

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth